Research Article
Human Paraoxonase-1 Activity Is Related to the Number of CD4+ T-Cells and Is Restored by Antiretroviral Therapy in HIV-1-Infected Individuals
Table 2
Highly active antiretroviral therapy (HAART) regimens of the study groups.
| | Antiretroviral therapy, (%)(1) | HAART () | EFV or NVP
292 (57) | LOP/r
217 (43) |
| | NNRTI-based | | | | Zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) + efavirenz (EFV) 600 mg (qd) | 153 (53) | — | | Stavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) + efavirenz (EFV) 600 mg (qd) | 26 (9) | — | | Zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) + nevirapine (NVP) 200 mg (bid) | 54 (18) | — | | Stavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) + nevirapine (NVP) 200 mg (bid) | 24 (9) | — | | Tenofovir (TDF) 300 mg + lamivudine (3TC) 150 mg (bid) + efavirenz (EFV) 600 mg (qd) | 16 (5) | — | | Tenofovir (TDF) 300 mg + lamivudine (3TC) 150 mg (bid) + nevirapine (NVP) 200 mg (bid) | 19 (6) | — | | PI-based | | | | Zidovudine (AZT) 300 mg + lamivudine (3TC) 150 mg (bid) + lopinavir/ritonavir (LOP/r) 400 mg/100 mg (bid) | — | 100 (47) | | Stavudine (d4T) 40 mg + lamivudine (3TC) 150 mg (bid) + lopinavir/ritonavir (LOP/r) 400 mg/100 mg (bid) | — | 117 (53) |
|
|
Note: NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor; bid: twice daily; qd: once daily; TDF: tenofovir; AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz; d4T: stavudine; NVP: nevirapine; LOP/r: lopinavir/ritonavir.
(1)Therapy with oral administration.
|
